Chetty, ManogariAli, Salma Abubaker Abbas2022-03-242024-04-162022-03-242024-04-162021https://hdl.handle.net/10566/11064Philosophiae Doctor - PhDThe incidence of Diffuse large B cell Lymphoma has been increasing lately at an alarming rate especially, in developing countries like Sudan. The standard therapy in Sudan is based solely on the R-CHOP chemotherapy regimen, yet it has been noticed that Diffuse Large B cell Lymphoma prognosis remains unfavorable. The late diagnosis and the consequent side-effects of the therapy directly affected the disease’s poor outcome. There is a scarcity of scientific publications regarding DLBCL in Sudan, but the increased burden necessitates the need for further research.enImmunophenotypic biomarkersDiffuse large B cell lymphomaSudanTumorWorld Health Organisation (WHO)University of Western Cape